{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:00:03Z","timestamp":1788908403274,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Longyan City Science and Technology Plan Project","award":["2024LYF17067"],"award-info":[{"award-number":["2024LYF17067"]}]},{"name":"Longyan City Science and Technology Plan Project","award":["2022LYF17043"],"award-info":[{"award-number":["2022LYF17043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although several drugs are associated with sexual dysfunction (SD), the SD-related risks of most drugs are not yet known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Our study will evaluate the risk signals of adverse drug event (ADE) that may be associated with SD in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to promote rational clinical drug use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SD-related drugs were examined using reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker. The top 60 drugs were identified based on the reported frequency and signal intensity. Univariate and multivariate regression analyses were used to explore the risk factors for drug-related SD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>The signal intensity between drug and SD was evaluated by signal detection method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 79\u2009022 SD-related ADEs were identified, including 61\u2009722 patients. The patients included 40\u2009273 males (65.25%) and 17\u2009777 females (28.80%), with more adults aged 18-65\u00a0years (52.29%). The three drugs with the highest ROR risk signals were finasteride (ROR [95% CI]: 212.3 [204.74-220.13]), dutasteride (ROR [95% CI]: 29.11 [26.84-31.56]), and silodosin (ROR [95% CI]: 21.81 [17.94-26.52]). Multivariate regression analysis showed that male, age 31-45\u00a0years, and 34 drugs including finasteride were risk factors for drug-related SD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Our findings emphasize the importance of the effects of drugs on SD and provide a reference point for further research on the pathogenesis of drug-related SD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and limitations<\/jats:title>\n                    <jats:p>Our study is the first to explore the potential association between medications and SD ADE using the FAERS database. However, as this study was a retrospective observational pharmacovigilance study, the causality could not be further assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We identified 34 drugs that may be related to SD, with a predominance in the nervous system. This finding suggests that clinicians should be aware of the risk of SD associated with these drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf227","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:19:58Z","timestamp":1756120798000},"page":"2058-2069","source":"Crossref","is-referenced-by-count":3,"title":["Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7205-4912","authenticated-orcid":false,"given":"Lihua","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Longyan First Affiliated Hospital of Fujian Medical University , Longyan, Fujian 364000 ,","place":["China"]},{"name":"The School of Pharmacy, Fujian Medical University , Fuzhou, Fujian 350122 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5417-9340","authenticated-orcid":false,"given":"Mei","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Longyan First Affiliated Hospital of Fujian Medical University , Longyan, Fujian 364000 ,","place":["China"]},{"name":"The School of Pharmacy, Fujian Medical University , Fuzhou, Fujian 350122 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Longyan First Affiliated Hospital of Fujian Medical University , Longyan, Fujian 364000 ,","place":["China"]},{"name":"The School of Pharmacy, Fujian Medical University , Fuzhou, Fujian 350122 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Longyan First Affiliated Hospital of Fujian Medical University , Longyan, Fujian 364000 ,","place":["China"]},{"name":"The School of Pharmacy, Fujian Medical University , Fuzhou, Fujian 350122 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2025110819141296700_ref1","first-page":"18","article-title":"Gender and sexual health: sexual dysfunction","volume":"449","author":"Stringer","year":"2016","journal-title":"FP Essent"},{"key":"2025110819141296700_ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2443956","article-title":"The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system","author":"Cheng","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2025110819141296700_ref3","doi-asserted-by":"publisher","first-page":"1423075","DOI":"10.3389\/fphar.2024.1423075","article-title":"The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study","volume":"15","author":"Cheng","year":"2024","journal-title":"Front Pharmacol"},{"issue":"40","key":"2025110819141296700_ref4","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1017\/S2045796024000441","article-title":"Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence","volume":"33","author":"David","year":"2024","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"11","key":"2025110819141296700_ref5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamapsychiatry.2023.2696","article-title":"Sexual dysfunction in schizophrenia: a systematic review and meta-analysis","volume":"80","author":"Th\u00e9o","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"3-4","key":"2025110819141296700_ref6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JRS-180744","article-title":"Enduring sexual dysfunction after treatment with antidepressants, 5\u03b1-reductase inhibitors and isotretinoin: 300 cases","volume":"29","author":"Healy","year":"2018","journal-title":"Int J Risk Saf Med"},{"issue":"7","key":"2025110819141296700_ref7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5694\/mja2.50522","article-title":"Antidepressant-induced sexual dysfunction","volume":"212","author":"Rothmore","year":"2020","journal-title":"Med J Aust"},{"issue":"5","key":"2025110819141296700_ref8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1192\/bjpo.bp.117.005538","article-title":"Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review","volume":"3","author":"Kaufman","year":"2017","journal-title":"BJPsych Open"},{"issue":"2","key":"2025110819141296700_ref9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.5114\/aoms.2017.65332","article-title":"Sexual health of male cardiac patients\u2014present status and expectations of patients with coronary heart disease","volume":"13","author":"Ka\u0142ka","year":"2017","journal-title":"Arch Med Sci"},{"key":"2025110819141296700_ref10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.22159\/ijpps.2020v12i2.34334","article-title":"A PILOT STUDY ON IDENTIFICATION AND MANAGEMENT OF DRUG INDUCED SEXUAL DYSFUNCTION: A COLLABORATIVE APPROACH BY CLINICAL PHARMACIST AND PSYCHIATRIST","volume":"20","author":"Shakya","year":"2020","journal-title":"Int J Pharm Pharm Sci"},{"issue":"6","key":"2025110819141296700_ref11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40264-022-01174-3","article-title":"Drug-induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database","volume":"45","author":"Valeiro","year":"2022","journal-title":"Drug Saf"},{"issue":"11-12","key":"2025110819141296700_ref12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1024\/0040-5930\/a000741","article-title":"Drug-induced sexual dysfunction","volume":"72","author":"Taegtmeyer","year":"2015","journal-title":"Ther Umsch"},{"issue":"5","key":"2025110819141296700_ref13","doi-asserted-by":"publisher","first-page":"3331024241248837","DOI":"10.1177\/03331024241248837","article-title":"Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?","volume":"44","author":"Al-Hassany","year":"2024","journal-title":"Cephalalgia."},{"issue":"12","key":"2025110819141296700_ref14","doi-asserted-by":"publisher","first-page":"e12396","DOI":"10.7759\/cureus.12396","article-title":"Uncommon case of oral vancomycin neurotoxicity with sexual dysfunction","volume":"12","author":"Almohammadi","year":"2020","journal-title":"Cureus."},{"issue":"10","key":"2025110819141296700_ref15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/14740338.2023.2223955","article-title":"Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)","volume":"22","author":"Mytheen","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2025110819141296700_ref16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1248\/bpb.35.967","article-title":"Adverse event profile of tigecycline: data mining of the public version of the US Food and Drug Administration adverse event reporting system","volume":"35","author":"Kadoyama","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"2025110819141296700_ref17","doi-asserted-by":"publisher","first-page":"17562864251315137","DOI":"10.1177\/17562864251315137","article-title":"Drug-induced dementia: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"18","author":"Xu","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"2025110819141296700_ref18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s11096-022-01425-4","article-title":"Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"44","author":"Huang","year":"2022","journal-title":"Int J Clin Pharm"},{"issue":"Pt 7","key":"2025110819141296700_ref19","doi-asserted-by":"publisher","first-page":"119010","DOI":"10.1016\/j.jep.2024.119010","article-title":"Ginkgo biloba extract safety: insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events","volume":"337","author":"Yao","year":"2025","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"2025110819141296700_ref20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jsxm.2016.01.019","article-title":"Psychological and interpersonal dimensions of sexual function and dysfunction","volume":"13","author":"Brotto","year":"2016","journal-title":"J Sex Med"},{"issue":"2","key":"2025110819141296700_ref21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/ijstd.IJSTD_67_20","article-title":"Female sexual dysfunction: a clinical case series","volume":"43","author":"Shenoi","year":"2022","journal-title":"Indian J Sex Transm Dis AIDS"},{"issue":"7","key":"2025110819141296700_ref22","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.1007\/s00210-024-03763-8","article-title":"Sexual dysfunctions associated with antipsychotic drug intake: a retrospective analysis of the FDA adverse events reporting system (FAERS)","volume":"398","author":"Engel","year":"2025","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"1","key":"2025110819141296700_ref23","doi-asserted-by":"publisher","first-page":"11236","DOI":"10.4081\/aiua.2023.11236","article-title":"Sexual dysfunction: time for a multidisciplinary approach?","volume":"95","author":"Cirillo","year":"2023","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"2025110819141296700_ref24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0035-1565100","article-title":"Sexual dysfunction related to drugs: a critical review. Part V: \u03b1-blocker and 5-ARI drugs","volume":"49","author":"La Torre","year":"2016","journal-title":"Pharmacopsychiatry."},{"key":"2025110819141296700_ref25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.euroneuro.2020.09.636","article-title":"Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study","volume":"41","author":"Dold","year":"2020","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"2025110819141296700_ref26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/andr.13515","article-title":"Exploring rat corpus cavernosum alterations induced by finasteride treatment and withdrawal","volume":"12","author":"Diviccaro","year":"2024","journal-title":"Andrology."},{"issue":"1","key":"2025110819141296700_ref27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-199957010-00014","article-title":"Finasteride: a review of its use in male pattern hair loss","volume":"57","author":"McClellan","year":"1999","journal-title":"Drugs."},{"issue":"3","key":"2025110819141296700_ref28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1515\/hmbci-2015-0015","article-title":"Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia","volume":"23","author":"Traish","year":"2015","journal-title":"Horm Mol Biol Clin Invest"},{"issue":"5","key":"2025110819141296700_ref29","doi-asserted-by":"publisher","first-page":"100543","DOI":"10.1016\/j.esxm.2022.100543","article-title":"Medications most commonly associated with erectile dysfunction: evaluation of the Food and Drug Administration National Pharmacovigilance Database","volume":"10","author":"Kaplan-Marans","year":"2022","journal-title":"Sex Med"},{"key":"2025110819141296700_ref30","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/NDT.S84528","article-title":"The influence of atypical antipsychotic drugs on sexual function","volume":"11","author":"Just","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"2025110819141296700_ref31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/YIC.0b013e32835e9112","article-title":"Iloperidone-induced retrograde ejaculation","volume":"28","author":"Freeman","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"2025110819141296700_ref32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/NDT.S185757","article-title":"Selective serotonin reuptake inhibitor-induced sexual dysfunction: current management perspectives","volume":"16","author":"Atmaca","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025110819141296700_ref33","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.clinsp.2025.100602","article-title":"Pharmacological treatment of antidepressant-induced sexual dysfunction in women: a systematic review and meta-analysis of randomized clinical trials","volume":"80","author":"de Aquino","year":"2025","journal-title":"Clinics (Sao Paulo)"},{"issue":"6","key":"2025110819141296700_ref34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1524-6175.2002.00862.x","article-title":"Sexual dysfunction in patients with hypertension: implications for therapy","volume":"4","author":"Ferrario","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025110819141296700_ref35","first-page":"28","article-title":"Men\u2019s health: male sexual dysfunction","volume":"503","author":"Rew","year":"2021","journal-title":"FP Essent"},{"key":"2025110819141296700_ref36","doi-asserted-by":"publisher","first-page":"1745506518762664","DOI":"10.1177\/1745506518762664","article-title":"Women\u2019s sexual dysfunction associated with psychiatric disorders and their treatment","volume":"14","author":"Basson","year":"2018","journal-title":"Womens Health (Lond)"},{"issue":"6","key":"2025110819141296700_ref37","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/j.1743-6109.2010.01742.x","article-title":"Prevalence of sexual dysfunction and impact of contraception in female German medical students","volume":"7","author":"Wallwiener","year":"2010","journal-title":"J Sex Med"},{"issue":"7","key":"2025110819141296700_ref38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14740338.2022.2049753","article-title":"Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management","volume":"21","author":"Winter","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2025110819141296700_ref39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/YCO.0000000000000198","article-title":"Sexual side-effects of antidepressant and antipsychotic drugs","volume":"28","author":"Montejo","year":"2015","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"2025110819141296700_ref40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14656566.2024.2446628","article-title":"Effects of alpha-1 adrenergic receptor blockers on erectile function: a systematic review","volume":"26","author":"Bakr","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"2025110819141296700_ref41","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/00325481.2015.1083394","article-title":"Time-to-onset and-resolution of adverse events before\/after atomoxetine discontinuation in adult patients with ADHD","volume":"127","author":"Upadhyaya","year":"2015","journal-title":"Postgrad Med"},{"issue":"8","key":"2025110819141296700_ref42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40264-013-0074-2","article-title":"Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis","volume":"36","author":"Camporeale","year":"2013","journal-title":"Drug Saf"},{"issue":"2","key":"2025110819141296700_ref43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/1039856218815746","article-title":"Case report: severe and treatment-resistant spontaneous ejaculation secondary to atomoxetine","volume":"27","author":"MacDonald","year":"2019","journal-title":"Australas Psychiatry"},{"issue":"7","key":"2025110819141296700_ref44","doi-asserted-by":"publisher","first-page":"e0308272","DOI":"10.1371\/journal.pone.0308272","article-title":"Sexual dysfunction among people with mental illness in Africa: a systematic review and meta-analysis study","volume":"19","author":"Fentahun","year":"2024","journal-title":"PLoS ONE"},{"issue":"8 Suppl. 9","key":"2025110819141296700_ref45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/s1092852900026729","article-title":"Sexual dysfunction in major depression","volume":"11","author":"Williams","year":"2006","journal-title":"CNS Spectr"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/11\/2058\/64282898\/qdaf227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/11\/2058\/64282898\/qdaf227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:14:19Z","timestamp":1762647259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/11\/2058\/8255541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2025,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf227","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,16]]}}}